^
Association details:
| Biomarker: | HER-2 E395K |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial
Published date:
06/01/2021
Excerpt:
LUX-Lung 8 (NCT01523587) enroled patients...Eligible patients had stage IIIB or IV lung SCC...amongst 132 afatinib-treated patients who underwent TGA, several biomarkers were more commonly observed in patients with long-term disease control than in the overall population. ERBB family mutations were of particular note, observed in five of 10 TGA patients (50%) with long-term benefit, and included EGFR (n = 2; R1052K and unknown)), ERBB2 (n = 2; Q57R, E395K)) and ERBB4 (n = 1; G668V; Fig. 3B).
DOI:
10.1016/j.eclinm.2021.100940
Trial ID:
